Modified-release nitrofurantoin in uncomplicated urinary tract infection
Mark Greener
Abstract
Mark Greener
Abstract
Uncomplicated urinary tract infection (UTI) is the most common bacterial infection presenting in the community ( Platt and Keating, 2007 ). UTIs can cause unpleasant and distressing symptoms and, occasionally, have serious consequences. Nevertheless, uncomplicated UTIs are eminently suitable for community management. Short courses of nitrofurantoin or trimethoprim—the firstline antibiotics—resolve more than 80% of UTIs ( Hummers-Pradier and Kochen, 2002 ). Modified-release nitrofurantoin should be associated with higher levels of compliance than conventional formulations of nitrofurantoin ( Claxton et al. 2001 ). Furthermore, despite entering the UTI armamentarium in 1953 ( Guay, 2001 ), nitrofurantoin resistance does not seem to have changed ( Kahlmeter, 2003 ; Nicolle et al, 2006 ). In contrast, resistance to trimethoprim may be rising to levels that may compromise the antibiotic's firstline position in UTI management ( Hummers-Pradier and Kochen, 2002 ). Against this background, modified-release nitrofurantoin is a suitable alternative—and is arguably preferable—to trimethoprim for the treatment of uncomplicated UTIs.
OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Uncomplicated urinary tract infection (UTI) is the most common bacterial infection presenting in the community ( Platt and Keating, 2007 ). UTIs can cause unpleasant and distressing symptoms and, occasionally, have serious consequences. Nevertheless, uncomplicated UTIs are eminently suitable for community management. Short courses of nitrofurantoin or trimethoprim—the firstline antibiotics—resolve more than 80% of UTIs ( Hummers-Pradier and Kochen, 2002 ). Modified-release nitrofurantoin should be associated with higher levels of compliance than conventional formulations of nitrofurantoin ( Claxton et al. 2001 ). Furthermore, despite entering the UTI armamentarium in 1953 ( Guay, 2001 ), nitrofurantoin resistance does not seem to have changed ( Kahlmeter, 2003 ; Nicolle et al, 2006 ). In contrast, resistance to trimethoprim may be rising to levels that may compromise the antibiotic's firstline position in UTI management ( Hummers-Pradier and Kochen, 2002 ). Against this background, modified-release nitrofurantoin is a suitable alternative—and is arguably preferable—to trimethoprim for the treatment of uncomplicated UTIs.
Key concepts: Nitrofurantoin, Medicine, Urinary system, Antibiotics, Trimethoprim, Intensive care medicine, Internal medicine, Antibiotic resistance